ID   PCI-15A
AC   CVCL_C184
SY   PCI15A; PCI-15; PCI-15T; PCI-15.1
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 987
DR   cancercelllines; CVCL_C184
DR   Cell_Model_Passport; SIDM00270
DR   Cosmic; 2131853
DR   Cosmic-CLP; 1240204
DR   DepMap; ACH-002294
DR   EGA; EGAS00001000978
DR   GDSC; 1240204
DR   GEO; GSM1670341
DR   PharmacoDB; PCI15A_1250_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54938668
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RX   PubMed=2766286;
RX   PubMed=8084624;
RX   PubMed=14996750;
RX   PubMed=17312569;
RX   PubMed=21868764;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29156801;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.36%; Native American=0.21%; East Asian, North=2.01%; East Asian, South=0%; South Asian=0.21%; European, North=62.27%; European, South=34.95% (PubMed=30894373).
CC   Derived from site: In situ; Pharynx, hypopharynx, pyriform sinus; UBERON=UBERON_8480022.
ST   Source(s): Cosmic-CLP; PubMed=21868764
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 11
ST   D16S539: 11
ST   D5S818: 11
ST   D7S820: 11
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C4943; Pyriform fossa squamous cell carcinoma
DI   ORDO; Orphanet_494547; Squamous cell carcinoma of the hypopharynx
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C756 ! PCI-15B
SX   Male
AG   69Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 25
//
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RA   Carey T.E.;
RT   "Head and neck tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994).
//
RX   PubMed=2766286;
RA   Heo D.S., Snyderman C.H., Gollin S.M., Pan S., Walker E., Deka R.,
RA   Barnes E.L., Johnson J.T., Herberman R.B., Whiteside T.L.;
RT   "Biology, cytogenetics, and sensitivity to immunological effector
RT   cells of new head and neck squamous cell carcinoma lines.";
RL   Cancer Res. 49:5167-5175(1989).
//
RX   PubMed=8084624; DOI=10.1177/01945998941113P105;
RA   Snyderman C.H., Klapan I., Milanovich M., Heo D.S., Wagner R.,
RA   Schwartz D.R., Johnson J.T., Whiteside T.L.;
RT   "Comparison of in vivo and in vitro prostaglandin E2 production by
RT   squamous cell carcinoma of the head and neck.";
RL   Otolaryngol. Head Neck Surg. 111:189-196(1994).
//
RX   PubMed=14996750; DOI=10.1158/0008-5472.CAN-03-2968;
RA   Wang J., Xi L.-Q., Hunt J.L., Gooding W., Whiteside T.L., Chen Z.,
RA   Godfrey T.E., Ferris R.L.;
RT   "Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in
RT   squamous cell carcinoma of the head and neck identifies a novel
RT   metastatic phenotype.";
RL   Cancer Res. 64:1861-1866(2004).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//